Results 51 to 60 of about 409,783 (282)

Tragedija slovenskega nacionalnega patentnega sistema

Economic and Business Review, 2019
The current Slovenian national patent system is supposed to provide incentives for innovation activity in the Slovenian economy while preventing the granting of unjustified monopolies, but the question arises whether this is the case.
Mitja Kovač, Rok Spruk
doaj   +1 more source

Incidence and Growth of Patent Thickets - The Impact of Technological Opportunities and Complexity [PDF]

, 2013
We investigate incidence and evolution of patent thickets. Our empirical analysis is based on a theoretical model of patenting in complex and discrete technologies. The model cap- tures how competition for patent portfolios and complementarity of patents
Aizcorbe, Alvarez, Amir, Arellano, Arellano, Beath, Bessen, Blundell, Callaert, Clark, Gallini, Graevenitz, Grindley, Hall, Hall, Hall, Holland, Jaffe, Jaffe, Kortum, Kortum, Kusonaki, Lee, Lerner, Loury, Meyer, Milgrom, Milo, Milo, Narin, Narin, National Research Council, Noel, Reinganum, Roberts, Scotchmer, Shapiro, Siebert, Somaya, Vives, Vives, Windmeijer, Ziedonis   +42 more
core   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Molecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen   +8 more
wiley   +1 more source

Patenting in Europe: The Jurisdiction of the CJEU over European Patent Law

Perspectives on Federalism, 2015
This paper will deal with EU competence over patent law, especially in the context of the TRIPS Agreement with reference to the ruling of CJEU in the Daiichi Sankyo case (CJEU case C-414/11 Daiichi Sankyo v DEMO Anonimos). The first part will explain the
Minn Mari
doaj   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

Interfacing of science, medicine and law: The stem cell patent controversy in the United States and the European Union

Frontiers in Cell and Developmental Biology, 2015
The patent eligibility of stem cells – particularly those derived from human embryos – has long been under debate in both the scientific and legal communities.
Sonya eDavey, Sonya eDavey, Neil eDavey, Qian eGu, Qian eGu, Na eXu, Rajet eVatsa, Samir eDevalaraja, Paul eHarris, Sreenivas eGannavaram, Raj eDave, Ananda eChakrabarty   +11 more
doaj   +1 more source

The market value of blocking patent citations [PDF]

There is a growing literature that aims at assessing the private value of knowledge assets and patents. It has been shown that patents and their quality as measured by citations received by future patents contribute significantly to the market value of ...
Czarnitzki, Dirk, Hussinger, Katrin, Leten, Bart   +2 more
core   +3 more sources

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Brexit – What are the potential consequences for pharma patents and SPCs

British Journal of Pharmacy, 2017
Brexit raises a number of difficult questions with regard to intellectual property rights in a post-Brexit world, particularly for UK based pharma companies.
Jamie Fraser, James Stones
doaj   +1 more source

Business Method Patents in Europe and their Strategic Use - Evidence from Franking Device Manufacturers [PDF]

, 2006
There has been a wide-spread misconception based on the imprecise wording of Art. 52 of the European Patent Convention (EPC) that the protection of business methods by patents is prohibited in Europe.
Wagner, Stefan
core   +2 more sources